Protalix appoints Shmuel Ben Zvi to board; stockholders approve share increase to 144M

Protalix BioTherapeutics, Inc.

Dr. Shmuel Ben Zvi appointed as independent director, joining Audit and Compensation Committees.
Stockholders approved amendment to increase authorized common shares from 120M to 144M.
Stockholders approved 2006 Stock Plan amendment raising available shares from ~5.7M to ~8.5M.
Advisory vote on executive compensation passed with ~80% of votes cast in favor.
All six director nominees elected; Kesselman & Kesselman ratified as auditor for FY2022.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shmuel Ben Zvi

Director

PLX · Protalix BioTherapeutics, Inc.

Effective: 2022-06-30
Filed: June 30, 2022, 7:59 PM ET

On June 29, 2022, the Board of Directors of Protalix BioTherapeutics, Inc. (the "Company") appointed Shmuel Ben Zvi, Ph.D. to serve on the Company’s Board of Directors, effective as of the adjournment of the Company’s 2022 Annual Meeting of Stockholders held on June 30, 2022 (the "Meeting").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shmuel Ben Zvi was appointed as Director at Protalix BioTherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 29, 2022, the Board of Directors of Protalix BioTherapeutics, Inc. (the "Company") appointed Shmuel Ben Zvi, Ph.D. to serve on the Company’s Board of Directors, effective as of the adjournment of the Company’s 2022 Annual Meeting of Stockholders held on June 30, 2022 (the "Meeting").

View on SEC.gov

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-010491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.